Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Moodys
Express Scripts
Baxter
Merck

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

GABLOFEN Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

When do Gablofen patents expire, and when can generic versions of Gablofen launch?

Gablofen is a drug marketed by Piramal Critical and is included in one NDA.

The generic ingredient in GABLOFEN is baclofen. There are twenty-one drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the baclofen profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Gablofen

A generic version of GABLOFEN was approved as baclofen by IVAX SUB TEVA PHARMS on July 21st, 1988.

  Try it Free

Drug patent expirations by year for GABLOFEN
Drug Prices for GABLOFEN

See drug prices for GABLOFEN

Recent Clinical Trials for GABLOFEN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Piramal Critical Care, Ltd.Phase 3
MallinckrodtPhase 3

See all GABLOFEN clinical trials

Pharmacology for GABLOFEN

US Patents and Regulatory Information for GABLOFEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Piramal Critical GABLOFEN baclofen INJECTABLE;INTRATHECAL 022462-001 Nov 19, 2010 AP RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Piramal Critical GABLOFEN baclofen INJECTABLE;INTRATHECAL 022462-003 Nov 19, 2010 AP RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Piramal Critical GABLOFEN baclofen INJECTABLE;INTRATHECAL 022462-002 Nov 19, 2010 AP RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
AstraZeneca
Boehringer Ingelheim
Mallinckrodt
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.